Full 2
Special Emphasis
on Neonatal Market

NITRIC OXIDE-RELEASING COMPOUND
FOR TREATMENT OF LUNG DISEASE

Read more
Full 2
Full 2
Our Mission

Our daily motivation is to defeat vaccine-resistant
COVID-19 infection

Read more
Full 2
Full 2
Our Company

Experienced scientists doing pioneering research
supported by funding from the National Institutes
of Health (NIH) and the U.S. Advanced Biomedical
Research and Development Agency (BARDA)

Read more
Full 2
Full 2
Our Science

Claritas is designing and developing drugs to work
in harmony with the body's natural defense
mechanisms to hasten and strengthen the body's
reaction to infections and other disorders

Read more
Full 2
previous arrow
next arrow

Nitric Oxide Technology

Claritas Pharmaceuticals is an innovative biotech company developing R-107 for the treatment of vaccine-resistant COVID strains.

Our scientific team has built a reputation for global leadership in basic science, drug development, and clinical medicine. Our expertise and professional network enable us to create groundbreaking opportunities that tackle drug development challenges.

R-107 was designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein.

Without a functional spike protein, the virus is rendered harmless due to its inability to enter and infect cells. Vaccines may fail when new mutations in the spike protein arise, but R-107 and the nitric oxide payload that it delivers will continue to render the virus harmless–regardless of how it may mutate.

> R-107 for Covid & Viral Infections
> R-107 and Vaccines
> Nitric Oxide Technology

A message from our Chairman, Robert Farrell

“I am often asked why we are focusing on nitric oxide as a treatment for coronavirus. The answer is simple: because we know it works.”
2 Lead Compounds
$25M Research Funding From The NIH And BARDA
2 Targeted Diseases
1 Billion People Affected By Targeted Diseases
read more

Class Acceleration Corp. A (CLAS:CA)

Go to Stock Watch

Quick links

Press Releases

11 Oct
Kalytera Therapeutics Inc. Completes Name Change to Claritas Pharmaceuticals, Inc

Company to Hold Annual and Special Meeting on June 17, 2021

SAN FRANCISCO, CA — (Apri...

11 Oct
Claritas Pharmaceuticals Issues Letter to Shareholders

SAN FRANCISCO, CA and TORONTO, ON — (May 11, 2021) – Claritas Pharmaceuticals, Inc. (TSX VEN...

11 Oct
Claritas Pharmaceuticals (formerly Kalytera Therapeutics) to Focus on Development of R-107 as a Therapy for Vaccine-Resistant COVID-19, Influenza, and Other Viral Infections

SAN FRANCISCO, CA and TORONTO, ON — (March 1, 2021) – Claritas Pharmaceuticals, Inc. (former...

11 Oct
Claritas Outlines Development Strategy for R-107 for Multiple Diseases, Disorders and Injuries

SAN FRANCISCO, CA and TORONTO, ON — (January 4, 2022) – Claritas Pharmaceuticals, Inc. (TSX ...